Skip to main content

Advertisement

SpringerLink
Log in

Reversible cardiogenic shock following 5-Fluorouracil infusion

  • SHORT REPORT
  • Published:
Investigational New Drugs Aims and scope Submit manuscript

Summary

5-fluorouracil remains a major component of chemotherapy regimens for various tumors. We report the case of reversible cardiogenic shock following 5-FU administration and discuss the different pitfalls of such toxicity. Oncologist should be aware of that rare but potentially lethal adverse event.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Longley DB, Harkin DP, Johnston PG (2003) 5-fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer 3:330–338. doi:10.1038/nrc1074

    Article  CAS  PubMed  Google Scholar 

  2. De Forni M, Malet-Martino MC, Jaillais P et al (1992) Cardiotoxicity of high-dose continuous infusion fluorouracil: a prospective clinical study. J Clin Oncol 10:1795–1801

    PubMed  Google Scholar 

  3. Meyer CC, Calis KA, Burke LB et al (1997) Symptomatic cardiotoxicity associated with 5-fluorouracil. Pharmacotherapy 17:729–736

    CAS  PubMed  Google Scholar 

  4. Akhtar SS, Salim KP, Bano ZA (1993) Symptomatic cardiotoxicity with high-dose 5-fluorouracil infusion: a prospective study. Oncology 50:441–444

    Article  CAS  PubMed  Google Scholar 

  5. Grandi AM, Pinotti G, Morandi E, Zanzi P, Bulgheroni P, Guasti L, Bertolini A, Venco A (1997) Noninvasive evaluation of cardiotoxicity of 5-fluorouracil and low doses of folinic acid: a one-year follow-up study. Ann Oncol 8(7):705–708. doi:10.1023/A:1008263321681

    Article  CAS  PubMed  Google Scholar 

  6. Teixeira L, Barry S, Debourdeau P, Cohen A, Tournigand C (2004) Cardiotoxicity of 5-fluorouracil. Bull Cancer 91(Suppl 3):154–158 Review

    PubMed  Google Scholar 

  7. Freeman NJ, Costanza ME (1988) 5-Fluorouracil-associated cardiotoxicity. Cancer 61(1):36–45. doi:10.1002/1097-0142(19880101)61:1<36::AID-CNCR2820610108>3.0.CO;2-6 Review

    Article  CAS  PubMed  Google Scholar 

  8. Mosseri M, Fingert HJ, Varticovski L et al (1993) In vitro evidence that myocardial ischemia resulting from 5-fluorouracil chemotherapy is due to protein kinase C-mediated vasoconstrication of vascular smooth muscle. Cancer Res 53:3028–3033

    CAS  PubMed  Google Scholar 

  9. Südhoff T, Enderle MD, Pahlke M, Petz C, Teschendorf C, Graeven U, Schmiegel W (2004) 5-Fluorouracil induces arterial vasocontractions. Ann Oncol 15(4):661–664. doi:10.1093/annonc/mdh150

    Article  PubMed  Google Scholar 

  10. Mizuno Y, Hokamura Y, Kimura T, Kimura Y, Kaikita K, Yasue H (1995) A case of 5-fluorouracil cardiotoxicity simulating acute myocardial infarction. Jpn Circ J 59:303–307

    CAS  PubMed  Google Scholar 

  11. Sasson Z, Morgan CD, Wang B, Thomas G, MacKenzie B, Platts ME (1994) 5-Fluorouracil related toxic myocarditis: case reports and pathological confirmation. Can J Cardiol 10(8):861–864

    CAS  PubMed  Google Scholar 

  12. Cwikiel M, Eskilsson J, Wieslander JB, Stjernquist U, Albertsson M (1996) The appearance of endothelium in small arteries after treatment with 5-fluorouracil. An electron microscopic study of late effects in rabbits. Scanning Microsc 10(3):805–818

    CAS  PubMed  Google Scholar 

  13. Porta C, Moroni M, Ferrari S, Nastasi G (1998) Endothelin-1 and 5-fluorouracil-induced cardiotoxicity. Neoplasma 45(2):81–82

    CAS  PubMed  Google Scholar 

  14. Kuzel T, Esparaz B, Green D, Kies M (1990) Thrombogenicity of intravenous 5-fluorouracil alone or in combination with cisplatin. Cancer 65(4):885–889

    Article  CAS  PubMed  Google Scholar 

  15. Barclay BJ, DeHaan CL, Hennig UG, Iavorovska O, von Borstel RW, von Borstel RC (2001) A rapid assay for mitochondrial DNA damage and respiratory chain inhibition in the yeast Saccharomyces cerevisiae. Environ Mol Mutagen 38(2–3):153–158. doi:10.1002/em.1066

    Article  CAS  PubMed  Google Scholar 

  16. Peters AK, Steemans M, Hansen E, Mesens N, Verheyen GR, Vanparys P (2008) Evaluation of the embryotoxic potency of compounds in a newly revised high throughput embryonic stem cell test. Toxicol Sci 105(2):342–350. doi:10.1093/toxsci/kfn126

    Article  CAS  PubMed  Google Scholar 

  17. Kosmas C, Kallistratos MS, Kopterides P, Syrios J, Skopelitis H, Mylonakis N, Karabelis A, Tsavaris N (2008) Cardiotoxicity of fluoropyrimidines in different schedules of administration: a prospective study. J Cancer Res Clin Oncol 134(1):75–82. doi:10.1007/s00432-007-0250-9

    Article  CAS  PubMed  Google Scholar 

  18. Van Cutsem E, Hoff PM, Blum JL et al (2002) Incidence of cardiotoxicity with oral fluoropyrimidine capecitabine is typical of that reported with 5-fluorouracil. Ann Oncol 13:484–485. doi:10.1093/annonc/mdf108

    Article  PubMed  Google Scholar 

Download references

Acknowledgement

The authors thank Lorna Saint Ange for editing.

Author information

Authors and Affiliations

  1. Phase I unit (SITEP), Department of Medicine, Institut Gustave Roussy, 94805, Villejuif, France

    Charles Ferté, Carlos Gomez Roca, Yohann Loriot, Rastislav Bahleda, Cristian Moldovan & Jean-Charles Soria

  2. Department of Cardiology, Saint-Antoine University and Medical School, Université Pierre et Marie Curie, Paris, France

    Ariel Cohen & Stephane Ederhy

  3. Department of Nephrology, Pitié-Salpêtrière Hospital, Paris, France

    Hassan Izzedine

Authors
  1. Charles Ferté
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Carlos Gomez Roca
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yohann Loriot
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Rastislav Bahleda
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Cristian Moldovan
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Ariel Cohen
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Hassan Izzedine
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Jean-Charles Soria
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Stephane Ederhy
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jean-Charles Soria.

Electronic Supplementary Material

Below is the link to the electronic supplementary material.

Panel 1

Transthoracic echocardiography performed before chemotherapy: apical 4 chamber view showing normal left ventricular ejection fraction (60%). (MPEG 460 kb)

Transthoracic echocardiography performed at H18 after 5FU infusion: apical 4 chamber view showing global hypokinesia with a severe LVEF dysfunction measured at 35 %. (MPEG 1204 kb)

Panel 3

Transthoracic echocardiography performed at Day 7: apical 4 chamber view showing a complete normalization of LVEF (60%). (MPEG 430 kb)

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ferté, C., Gomez Roca, C., Loriot, Y. et al. Reversible cardiogenic shock following 5-Fluorouracil infusion. Invest New Drugs 28, 531–533 (2010). https://doi.org/10.1007/s10637-009-9271-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10637-009-9271-3

Keywords

Search

Navigation